The phrase “viral vector” sounds ominous, like something from a movie about spies and internet intrigue. It refers to a practical delivery system for the gene of your choice. If you are a biomedical researcher and you want to tweak genes in a particular part of the body in an experimental animal, viral vectors are the way to go.
Emory’s Viral Vector Core was started when eminent neuroscientist Kerry Ressler was at Emory and is now overseen by geneticist Peng Jin. Technical director Xinping Huang and her colleagues can produce high-titer viral vectors, lentivirus and AAV. Discuss with her the best choice. It may depend on the size of the genetic payload you want to deliver and whether you want the gene to integrate into the genome of the target cell.
As gene therapy and CRISPR/Cas9-style gene editing research progresses, we can anticipate demand for services such as those provided by the Viral Vector Core. [Clinical applications are close, but will not be dealt with in the same place!]
Note: the lentiviruses used in viral vector applications were originally derived from HIV, but the cells used for packaging and viral production can’t make infectious virus – four different plasmids are used to transiently express the packaging proteins. Emory’s neuroscience-oriented core facilities are supported by a grant from the National Institute of Neurological Disorders and Stroke.
About the author
Science Writer, Research Communications email@example.com 404-727-7829 Office